Mass spectrometry of murine leukemia virus core proteins

Journal of Virological Methods

Volumn 169, Issue 2, 2010, Pages 290-295

  Medvedkin, Viacheslav ^a   Moore, Roger ^b   Falick, Arnold M ^c   Conner, John ^a   Omelchenko, Tatiana ^a   Young, Mary ^b   Anderson, W French ^a   Golubkov, Vladislav S ^d   Rozenberg Adler, Yanina ^e  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c Perseptive Biosystems   (United States)

^d BURNHAM INSTITUTE   (United States)

^e San Diego Cancer Research Institute   (United States)

Author keywords

Core proteins; Gene therapy; Mass spectrometry; MuLV; Murine leukemia virus

Indexed keywords

CORE PROTEIN; CYSTEINE; METHIONINE; RETROVIRUS VECTOR;

ARTICLE; COMPLEX FORMATION; ELECTROSPRAY MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR WEIGHT; MURINE LEUKEMIA VIRUS; MYRISTYLATION; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; ULTRACENTRIFUGATION; VIRUS PARTICLE; VIRUS PURIFICATION;

LEUKEMIA VIRUS, MURINE; PROTEIN PROCESSING, POST-TRANSLATIONAL; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; ULTRACENTRIFUGATION; VIRAL CORE PROTEINS;

MURINE LEUKEMIA VIRUS;

EID: 77957016308     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2010.07.028     Document Type: Article

References (20)

1. Albrethsen J. Reproducibility in protein profiling by MALDI-TOF mass spectrometry. Clin. Chem. 2007, 53:852-858.
2. Bothner B., Siuzdak G. Electrospray ionization of a whole virus: analyzing mass, structure, and viability. Chembiochem 2004, 5:258-260.
3. Chen G., Pramanik B.N. Application of LC/MS to proteomics studies: current status and future prospects. Drug Discov. Today 2009, 14:465-471.
4. Davis M.T., Lee T.D. Rapid protein identification using a microscale electrospray LC/MS system on an ion trap mass spectrometer. J. Am. Soc. Mass Spectrom. 1998, 9:194-201.
5. Downard K.M., Morrissey B., Schwahn A.B. Mass spectrometry analysis of the influenza virus. Mass Spectrom. Rev. 2009, 28:35-49.
6. Henderson L.E., Krutzsch H.C., Oroszlan S. Myristyl amino-terminal acylation of murine retrovirus proteins: an unusual post-translational proteins modification. Proc. Natl. Acad. Sci. U.S.A. 1983, 80:339-343.
7. Henderson L.E., Sowder R., Copeland T.D., Smythers G., Oroszlan S. Quantitative separation of murine leukemia virus proteins by reversed-phase high-pressure liquid chromatography reveals newly described gag and env cleavage products. J. Virol. 1984, 52:492-500.
8. Januszeski M.M., Cannon P.M., Chen D., Rozenberg Y., Anderson W.F. Functional analysis of the cytoplasmic tail of Moloney murine leukemia virus envelope protein. J. Virol. 1997, 71:3613-3619.
9. Lewis J.K., Bendahmane M., Smith T.J., Beachy R.N., Siuzdak G. Identification of viral mutants by mass spectrometry. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:8596-8601.
10. Miller A.D., Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol. Cell. Biol. 1986, 6:2895-2902.
11. Moore R.E., Licklider L., Schumann D., Lee T.D. A microscale electrospray interface incorporating a monolithic, poly(styrene-divinylbenzene) support for on-line liquid chromatography/tandem mass spectrometry analysis of peptides and proteins. Anal. Chem. 1998, 70:4879-4884.
12. Morgan R.A., Nussbaum O., Muenchau D.D., Shu L., Couture L., Anderson W.F. Analysis of the functional and host range-determining regions of the murine ectropic and amphotropic retrovirus envelope proteins. J. Virol. 1993, 67:4712-4721.
13. Pitha P.M., Staal S.P. Effect of interferon on murine leukemia virus infection. III. Effect of interferon on MSV-induced transformation. Virology 1978, 90:151-155.
14. Powell S.K., Kaloss M., Burimski I., Weaver L., Long Z., Lyons R., McGarrity G.J., Otto E. In vitro analysis of transformation potential associated with retroviral vector insertions. Hum. Gene Ther. 1999, 10:2123-2132.
15. Qiao J., Moreno J., Sanchez-Perez L., Kottke T., Thompson J., Caruso M., Diaz R.M., Vile R. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment. Gene Ther. 2006, 13:1457-1470.
16. Segura M.M., Garnier A., Di Falco M.R., Whissell G., Meneses-Acosta A., Arcand N., Kamen A. Identification of host proteins associated with retroviral vector particles by proteomic analysis of highly purified vector preparations. J. Virol. 2008, 82:1107-1117.
17. Shinnick T.M., Lerner R.A., Sutcliffe J.G. Nucleotide sequence of Moloney murine leukaemia virus. Nature 1981, 293:543-548.
18. Stephenson J.R., Reynolds F.H., van de Ven W.J. Abelson murine leukemia virus: characterization of a polyprotein containing phosphorylated component(s) encoded by newly acquired sequences. Arch. Geschwulstforsc. 1980, 50:204-213.
19. Trinh A.T., Ball B.G., Weber E., Gallaher T.K., Gluzman-Poltorak Z., Anderson F., Basile L.A. Retroviral vectors encoding ADA regulatory locus control region provide enhanced T-cell-specific transgene expression. Genet. Vaccines Ther. 2009, 7:13.
20. Van Vliet K., Mohiuddin Y., McClung S., Blouin V., Rolling F., Moullier P., Agbandje-McKenna M., Snyder R.O. Adeno-associated virus capsid serotype identification: analytical methods development and application. J. Virol. Methods 2009, 159:167-177.